Topics

Celgene seeks EMA approval for luspatercept for anemia associated with MDS and beta-thalassemia

06:51 EDT 29 Apr 2019 | Pharmaceutical Business Review

Luspatercept is an erythroid maturation agent (EMA), which has been designed to regulate late-stage red blood cell maturation. The drug is being jointly developed by Acceleron and Celgene

The post Celgene seeks EMA approval for luspatercept for anemia associated with MDS and beta-thalassemia appeared first on Pharmaceutical Business review.

Original Article: Celgene seeks EMA approval for luspatercept for anemia associated with MDS and beta-thalassemia

NEXT ARTICLE

More From BioPortfolio on "Celgene seeks EMA approval for luspatercept for anemia associated with MDS and beta-thalassemia"

Quick Search

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...